Receptors, Urokinase Plasminogen Activator
"Receptors, Urokinase Plasminogen Activator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An extracellular receptor specific for UROKINASE-TYPE PLASMINOGEN ACTIVATOR. It is attached to the cell membrane via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and plays a role in the co-localization of urokinase-type plasminogen activator with PLASMINOGEN.
Descriptor ID |
D055293
|
MeSH Number(s) |
D12.776.395.550.448.813 D12.776.543.484.500.813 D12.776.543.550.418.813 D12.776.543.750.815
|
Concept/Terms |
Receptors, Urokinase Plasminogen Activator- Receptors, Urokinase Plasminogen Activator
- CD87 Antigen
- Antigen, CD87
- Plasminogen Activator Receptor, Urokinase Type
- Plasminogen Activator, Urokinase Receptor
- Urokinase-Type Plasminogen Activator Receptors
- Urokinase Type Plasminogen Activator Receptors
- Receptor, Pro-Urokinase
- Pro-Urokinase Receptor
- Receptor, Pro Urokinase
- Receptor, Urokinase Plasminogen Activator
- U-PA Receptor
- Receptor, U-PA
- U PA Receptor
- Upar Receptor
- Receptor, Upar
- Urokinase Plasminogen Activator Receptors
- Antigens, CD87
- CD87 Antigens
- Plasminogen Activator, Urokinase Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Urokinase Plasminogen Activator".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Urokinase Plasminogen Activator".
This graph shows the total number of publications written about "Receptors, Urokinase Plasminogen Activator" by people in this website by year, and whether "Receptors, Urokinase Plasminogen Activator" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2008 | 1 | 1 | 2 |
2009 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Urokinase Plasminogen Activator" by people in Profiles.
-
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020 01; 106:102340.
-
CHD4-regulated plasmin activation impacts lymphovenous hemostasis and hepatic vascular integrity. J Clin Invest. 2016 06 01; 126(6):2254-66.
-
Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells. Anticancer Res. 2015 Oct; 35(10):5263-70.
-
The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 2013; 9(12):e1004031.
-
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 2009; 84(5):271-5.
-
Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells. Biochem Cell Biol. 2008 Dec; 86(6):477-86.
-
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008 Oct; 111(1):89-94.
-
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Res. 2007 Sep-Oct; 27(5A):3435-9.
-
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res. 2006 May-Jun; 26(3A):1745-51.
-
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol. 2003 Oct; 52(4):270-6.